Ph.D., CEO & Co-founder, Panakeia
Biography
Dr Pahini Pandya is the CEO and co-founder of Panakeia Technologies, which enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images, using AI and without the need for any lab assays. Trained as a cancer researcher Dr. Pahini Pandya spent the last decade furthering translational research in the field. She pursued a PhD in cancer biophysics at King’s College London, a postdoc at the University of Cambridge and has several publications in top journals. Educated at the Stanford and Cambridge business schools, Pahini has also held several leadership positions across entrepreneurial organisations and helped numerous start-ups commercialise research. She has been recognised as Global Shaper by the World Economic Forum, and received multiple awards for entrepreneurship.
Clinical Dx Showcase:
Panakeia
Panakeia enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images, using AI and without the need for any lab assays.
TBC
Overview of Panakeia's approach for digital biomarker profiling of cancer tissues and applicability for research and clinic.
Session Abstract – PMWC 2022 Silicon Valley
Track 6 - June 28 9.00 A.M.-4.45 P.M.,Track 6 - June 29 3.30 P.M.-3.45 P.M.,Track 6 - June 30 9.00 A.M.-1.15 P.M.
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
